CD8A and melanoma: Moreover, patients with melanoma who respond to anti-PD-1 therapy displayed increased intratumoral CD8+ T cells which were associated with tumor regression.472 Caroline Robert et al.473 reported significantly longer overall survival in patients with previously untreated metastatic melanoma using combination therapy of ipilimumab and dacarbazine.